Hunchaisri Niran
Department of Otolaryngology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand.
J Med Assoc Thai. 2012 Jan;95(1):73-80.
To evaluate the efficacy of domperidone in combination with omeprazole in the treatment of laryngopharyngeal reflux (LPR) compare to omeprazole alone.
A prospective and randomized study included seventy patients with a reflux symptom index (RSI) 13 or more. They received either domperidone 10 mg thrice daily plus omeprazole 20 mg twice daily or omeprazole alone for three months. RSI was assessed at baseline and after three months of treatment.
Total RSI as well as several subscores were comparable between groups before the treatment. After three months of the treatment, moderate improvement of total RSI was shown in both groups (72.7%, 67.5%). The reduction of total RSI and individual subscores were statistically significant within each group (p < 0.001 each). Comparing between each treatment group, the mean difference of total RSI and individual subscores did not shown any statistically differences (p > 0.05 each) at the end of the study period.
Domperidone in combination with omeprazole is not superior to omeprazole alone in the treatment of LPR.
评估多潘立酮联合奥美拉唑治疗喉咽反流（LPR）的疗效，并与单用奥美拉唑进行比较。
一项前瞻性随机研究纳入了70例反流症状指数（RSI）为13或更高的患者。他们接受每日三次10毫克多潘立酮加每日两次20毫克奥美拉唑治疗，或仅接受奥美拉唑治疗三个月。在基线和治疗三个月后评估RSI。
治疗前两组的总RSI以及几个子分数相当。治疗三个月后，两组的总RSI均有中度改善（72.7%，67.5%）。每组内总RSI和各个子分数的降低均具有统计学意义（每组p < 0.001）。在研究期结束时，比较各治疗组，总RSI和各个子分数的平均差异均无统计学差异（每组p > 0.05）。
多潘立酮联合奥美拉唑治疗LPR并不优于单用奥美拉唑。
